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Responsive population dynamics and wide
seeding into the duodenal lamina propria of
transglutaminase-2-specific plasma cells in
celiac disease
R Di Niro1, O Snir2, K Kaukinen3, G Yaari4, KEA Lundin2,5, NT Gupta6, SH Kleinstein6,7, M Cols8,
A Cerutti8, M Ma¨ki9, MJ Shlomchik1 and LM Sollid2
A hallmark of celiac disease is autoantibodies to transglutaminase 2 (TG2). By visualizing TG2-specific antibodies by
antigen staining of affectedgut tissue,we identified TG2-specific plasmacells in the laminapropria aswell as antibodies
in the subepithelial layer, inside the epithelium, andat the brushborder. The frequencyof TG2-specific plasmacellswere
found not to correlate with serum antibody titers, suggesting that antibody production at other sites may contribute to
serum antibody levels. Upon commencement of a gluten-free diet, the frequency of TG2-specific plasma cells in the
lesiondroppeddramaticallywithin 6months, yet somecells remained. The frequencyof TG2-specific plasmacells in the
celiac lesion is thusdynamically regulated in response toglutenexposure. Lasermicrodissectionofplasmacell patches,
followedby antibody gene sequencing, demonstrated that clonal cellswere seeded in distinct areasof themucosa. This
was confirmed by immunoglobulin heavy chain repertoire analysis of plasma cells isolated from individual biopsies of
two untreated patients, both for TG2-specific and non-TG2-specific cells. Our results shed new light on the processes
underlying the B-cell response in celiac disease, and the approach of staining for antigen-specific antibodies should be
applicable to other antibody-mediated diseases.
INTRODUCTION
Celiac disease (CD) is amultifactorial disorder characterized by
an intestinal inflammatory response to ingested cereal gluten
proteins.1 The human leukocyte antigen association and the
central role of CD4þ Tcells in the pathogenesis are thoroughly
investigated.2 T cells of the lesion recognize gluten peptides that
are deamidated in vivo by the enzyme transglutaminase 2
(TG2).3,4 Notably, the great majority of CD patients develop
an autoantibody response, with TG2 itself being the main
autoantigen.5 It is not known whether these antibodies have
a role in the pathophysiology of CD, yet anti-TG2 immuno-
globulin A (IgA) antibodies are increasingly used as diag-
nostic tool6 and in the follow-up of the treatment, as upon
commencement of a gluten-free diet (GFD) autoantibodies
disappear from serum within months.7 Anti-TG2 antibodies
are produced by plasma cells (PCs) localized in the lamina
propria of the intestinal mucosa,8–10 but PCs localized else-
where may also contribute to the antibody production.
Korponay-Szabo et al.11 developed a double-color immuno-
fluorescencemethod that allowed visualizing antibody deposits
in correspondence with the subepithelial TG2 layer in the small
intestine, as well as in other tissues. This method builds on
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colocalization between IgA and the TG2 protein, the latter
usually identified by means of the CUB7402 murine mono-
clonal antibody. Importantly, this has been proposed as a tool
for early diagnosis12 on affected individuals without signs of
villous atrophy13,14 or with negative/borderline serology.15
Recently, we reported a flow cytometry-based method to
describe and enumerate TG2-specific PCs from freshly
obtained biopsies of the small intestine of CD patients.10
We found that in untreated CD patients the frequency of these
cells was exceptionally high, and that they produced antibodies
with limited somatic hypermutation but nonetheless reason-
able affinity. In the same work we reported an immunofluor-
escence-based method to visualize TG2-specific PCs on
cryosections. As this material can be stored for prolonged
periods of time and requires relatively little amount of
specimen, studies on cryosections provide a simple yet very
valid alternative for the analysis of intestinal humoral
responses. Even though significant discoveries of the anti-
TG2 antibody response have been done, its importance in the
diagnostic workup of CD and the unknown role in the
pathogenesis of the disease suggest that more research on this
topic is necessary. In this work, we expand our previous
findings on the intestinal anti-TG2 response by investigating
and describing the location of TG2-specific PCs and antibodies,
the phenotype of these cells as well as the niche supporting
them, and the kinetics of their disappearance upon commence-
ment of a GFD, and we discuss a mechanism for a possible
pathogenic involvement. Our findings provide a new tool to
analyze the antibody response in CD and in general the
specificity of antibody responses directly in affected tissues.
RESULTS
TG2-specific plasma cells are abundant and accumulate
close to the gut lumen in the celiac lesion
We recently reported that the frequency of TG2-specific cells in
the intestinal lesion of untreated CD patients is exceptionally
high, averaging 10%. Here, we further investigate this matter by
using our novel immunofluorescence technique10 that takes
advantage of soluble biotinylated TG2 to visualize intracellular
deposits of anti-TG2 antibodies that, in combination with an
anti-CD138 antibody, allowed us to directly identify TG2-
specific PCs (Figure 1). This method differs from the
CUB7402/IgA costaining method11 that reveals the location
of the TG2 protein in the tissue, and indirectly the presence of
specific antibody deposits because of the colocalization with
IgA. At low magnification ( 10), stained cryosections from
untreated CD patients (Figure 1a,b) showed significant
plasmacytosis in the lamina propria,16 and the localization
of the PCs in the lamina propria was more toward the intestinal
lumen than in healthy controls (Figure 1d). Figure 1c is
representative of the most common condition observed in
GFD-treated patients, with good recovery of the intestinal
morphology, markedly decreased plasmacytosis, and the
presence of a few residual TG2-specific PCs. In fact, despite
the diet, we usually do not observe a complete disappearance of
TG2-specific PCs.
Interestingly, in patients with active disease we consistently
observed that TG2-specific PCswere preferentially found in the
lamina propria in proximity of the lumen, as evident from
Figure 1a,b and further shown in Figure 1e at higher
magnification ( 40). The single channel images showed
that all the TG2þ cells express with the anti-CD138 marker,
demonstrating that these are PCs.
Double-color immunofluorescence studies of in situ loca-
lization ofTG2 and IgA suggested that inCDpatients, anti-TG2
antibodies are deposited with TG2 in the subepithelial layer.11
Here by using biotinylated TG2 as bait for specific antibodies,
we were able to visualize antibodies not only within PCs
(as described above), but also at their extracellular location as
deposits, primarily in the subepithelial layer in association with
TG2, as expected (Figure 1f). Furthermore, inmany cases TG2-
specific antibodies seemed to be present in the epithelial cells
and at the brush border in CD patients, as shown in Figure 1g.
Although it can be argued that visualization of subepithelial
deposits by biotin-labeled recombinant TG2may be sensitive to
artifacts because of unspecific binding of the bait to endogenous
fibronectin,15 this does not seem to be an issue under the
conditions used here. In fact in healthy controls who do not
produce anti-TG2 antibodies, but also possess the fibronectin-
TG2 subepithelial layer (Figure 1g), only weak binding of the
bait to fibronectin was observed (for instance, compare
Figure 1d with Figure 1a,b).
TG2-specific plasma cells of the mucosa drop 6 months
after commencement of a GFD
The ability to stain antigen-specific PCs in frozen samples by
immunofluorescence, as well as the availability of biopsies
taken from the same patients at different times and stored in the
freezer, allowed us to study the kinetics of the disappearance of
TG2-specific PCs at early stages of GFD. We collected frozen
cryosections of intestinal specimens from CD patients at
diagnosis and after 6, 12, or 24months ofGFD, and enumerated
TG2-specific PCs by immunofluorescence. The results are
reported in Figure 2a as percentage of TG2-specific cells in the
PC compartment. All patients had elevated amounts of these
cells at diagnosis (n¼ 15, average 9.6%, range 3.0–18.6%), and
this frequencymarkedly decreased during the periodwithGFD.
After 6 and 12 months of diet, TG2-specific cells dropped to an
average of 1.7% (n¼ 6, range 0–4.1%) and 1.4% (n¼ 9, range 0–
5.7%) respectively. For 3 patients from whom we were able to
obtain an additional specimen after 24 months of GFD, we did
not detect any TG2-specific PCs at this time point. However, in
these patients TG2-specific PCs were absent or in low amounts
already at the first sampling (0 and 0.9% in the 2 patient samples
after 6 months, and 0% for 1 patient sampled at 12 months). As
in some cases a relatively high frequency of TG2-specific PCs
was still detected after 6–12months of GFD, and as some of the
patients included in this study had borderline or positive
serology according to endomysial antibodies or IgA anti-TG2
despite GFD (yellow dots in Figure 2a), we asked whether
residual presence of TG2-specific PCs correlated with sero-
positivity. This was not the case at 6months, as all of the cases at
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this time point were below cutoff for serum IgA anti-TG2
positivity (according to the Celikey test). Of the 5 patients who
were seropositive or borderline seropositive at 12months, 3 had
detectable TG2-specific intestinal plasma cells. These findings
raise the question of whether in general the TG2-specific PC
frequency in untreated patients correlates with their serum
titer. As shown in Figure 2b, we found no correlation between
PC frequency and serum titer. This may be because of the
presence of patches in the intestinal lesion with different
densities of TG2-specific PCs, and therefore one single biopsy
specimen may not be representative of the small intestine in its
entirety. In an attempt to address this, from one patient wewere
Figure 1 Visualization of transglutaminase 2 (TG2)-specific plasma cells (PCs) and antibodies by immunofluorescence on cryosections from celiac
disease (CD) patients. (a–d) Low-magnification images of sections from two untreated patients, one gluten-free diet (GFD)-treated patient, and one
control individual. TG2-specific plasma cells (identified by costaining for the CD138 plasma cell marker, in red, and TG2-specific antibody deposits as
revealed by the biotinylated TG2 antigen, in green) are evident in untreated patients, decreased in theGFD-treated patient, and absent in the control. (e)
Higher-magnification images from an untreated patient, further revealing the apical localization of TG2-specific plasma cells (intracellular antibody
deposits as revealed by biotinylated TG2, in green, as shown in center and right panels). (f) Colocalization of immunoglobulin A (IgA) and anti-TG2
antibodies (as detected by biotinylated TG2), showing PCs and deposits in the lamina propria, as well as additional deposits in the subepithelial layer and
on the brush border. (g) Colocalization of IgA andTG2 (as detected by the anti-TG2monoclonal antibody (mAb)CUB7402), showing a different pattern in
CD patients and controls, with extensive overlap between the two stainings observed in CD patients only.
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able to obtain three biopsies sampled from different intestinal
locations. Flow cytometry quantification of TG2-specific PCs
showed consistent frequency among the three samples (4.5, 4.0,
and 4.3%, Figure 2c) and these data, although they need to be
substantiated, speak toward a fairly homogenous distribution
of autoreactive PCs in biopsies of the upper small bowel of CD
patients.
To further understand the factors regulating TG2-specific
plasma cell survival, we also investigated the PC expression of
TACI (transmembrane activator and calcium modulator and
cyclophilin ligand interactor), BCMA (B-cell maturation
antigen), and BAFF-R (B-cell activating factor receptor) that
are receptors for BAFF and APRIL (a proliferation-inducing
ligand) involved in B-cell survival. Staining gut tissue sections
with TACI- and BAFF-R-specific antibodies showed that TACI
was expressed in a subset of PCs, and in some cases its
expression was paired to that of BAFF-R (Figure 3a,b). A
similar heterogeneity regarding these markers was observed in
TG2-specific cells, with no significant difference compared
with other PCs (Figure 3c). A significant fraction of PCs
appeared to express BCMA (Figure 3d). In order to improve
the analysis of BAFF and APRIL receptors, we used a flow
cytometry approach that yields a more quantitative and
objective set of data. Figure 3e and 3f shows the percen-
tage of IgA PCs expressing BCMA, BAFF-R, or TACI as judged
by staining of single-cell suspensions of biopsies of five
untreated CD patients. These data confirmed BCMA
expression on most plasma cells, whereas BAFF-R and
TACI were expressed only by a subgroup of cells and at
variable levels. There were no significant differences in the
relative expression of these markers between TG2-specific and
non-TG2-specific PCs, suggesting that these receptors play a
role in the development of the PC compartment in the gut, but it
does not appear that the autoimmune B-cell response in CD
differs significantly from its physiological counterpart.
Similarly, the expression levels of BCMA and BAFF-R were
similar in CD patients and healthy controls, whereas TACI
appeared to be expressed at slightly higher levels inCDpatients,
although the difference did not reach statistical significance
(P¼ 0.055, Mann–Whitney; Figure 3g).
Analysis of PCs dissemination in the gut mucosa by laser
capture and microdissection
To investigate whether intestinal PC populations expand
locally or at a distant site, we performed laser capture and
microdissection followed by sequencing of immunoglobulin
heavy chain variable (IGHV) genes on patches with such cells
from intestinal biopsies of CD patients. To this end, we adapted
a published set of primers for a seminested PCR of antibody
genes on genomic DNA. Because of the available microscope
configuration, the procedure was optimal for dissecting
sections stained by immunohistochemistry under transmitted
light. Preliminary experiments indicated that staining for the
CD138 marker was optimal under these conditions, and we
used this marker to stain sections from samples known to have
high frequency of TG2-specific PCs (identified using the
standard immunofluorescencemethod shown in Figure 1).We
dissected patches comprising 20 to 30 PCs (an example is
shown in Figure 4a) from one patient with active CD. In order
to increase the variability of the analysis, the same patch was
picked from three consecutive slides. We amplified genomic
DNA and obtained a PCR product from all of the picks, and
built and sequenced libraries. Importantly, several IGHV-5
sequences with few or no mutations were found; IGHV-5
genes had on average 2.2 mutations (n¼ 9) as compared with
other genes that averaged 11.4 mutations/sequence (n¼ 33).
Although not a formal demonstration, this strongly suggests
specificity for TG2 of some of the dissected cells; in fact, as us
Figure 2 Quantification of TG2-specific plasmacells. (a) Kinetics of the disappearance of transglutaminase 2 (TG2)-specific plasmacells (PCs) at early
(6 months) or later (12 and 24 months) stages of gluten-free diet (GFD), as determined using our standard immunofluorescence staining technique
showed in Figure 1a–e. Ab, antibody; EMA, endomysial antibody. (b) Lack of correlation between the TG2–immunoglobulin A (IgA) serum titer and the
PC count in the biopsy, as assessed at the time of small intestinal biopsy sampling in patients with active disease. (c) Frequency of TG2-specific plasma
cells in three different biopsy samples from the samepatient, as determined by flow cytometry usingmultimerized labeled TG2 as bait for antigen-specific
cells.
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Figure 3 Analysis of the expression of BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand) receptors on the plasma cell (PC)
populations in the lamina propria. (a–f) Visualization of transglutaminase 2 (TG2)-specific PCs by immunofluorescence on gut biopsy cryosections of
celiac disease (CD) patients, with characterization of their phenotype and the supporting niche. Images are representative of stainings performed on two
or three CD patients and two healthy controls. (e) Quantitative analysis of the expression of BCMA (B-cell maturation antigen), BAFF-R (B-cell activating
factor receptor), and TACI (transmembrane activator and calcium modulator and cyclophilin ligand interactor) by flow cytometry using monoclonal
antibodies and multimerized TG2 antigen. Panels indicate percentage of cells expressing BCMA, BAFF-R, and TACI, shown for TG2-specific and non-
TG2-specific IgA PCs. Box plots with minimum and maximum values are shown. The results derive from analysis of five untreated CD patients.
(f) Panels showing flow cytometry plots for one of the subjects. Receptor expression by TG2-specific PCs is shown in blue and non-TG2-specific PCs in
light red. The gray curves to the left in each flow diagram represent baseline (FluorescenceMinusOne (FMO)). (g)Comparison of the expression levels of
BCMA, BAFF-R, and TACI by flow cytometry of immunoglobulin A (IgA) PCs from gut biopsies of five untreated CD patients and five healthy controls.
Percentage positive cells with box plots giving minimum and maximum values are shown.
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and others have reported,10,17 IGHV-5 genes with low degree of
somatic hypermutation are otherwise rare among the intestinal
PC compartment. Interestingly, in some cases clonal sequences
were found that showed shared and unique mutations, thus
raising the possibility that such clones mutate and evolve
locally. We further extended our analysis and compared
sequences found in different patches that were sampled from an
additional patient with an active disease. We dissected four PC
patches (named A, B, C, and D) that were not adjacent to each
other. The same patch was dissected from several consecutive
slides. Libraries were obtained from 14 picks, yielding 53
unique sequences representing 26 different clones; 18 were
represented by one single sequence and 8 by 2 or more and
allowed us to build lineage trees.Table 1 provides a summary of
the eight clonal trees that were built with sequences from this
patient: whereas a few simple trees could be built from clonal
sequences that were found only within one of the patches
(example in Figure 4b, with sequences derived from one single
patch, clone ID 23 according to Table 1), in many other cases
larger trees could be built where several different patches
contributed clones (example in Figure 4c, with sequences from
three different patches, clone ID 22 according to Table 1).
Analysis of clonal relatedness by high-throughput
sequencing of PCs from multiple individual biopsies
This limited sequence analysis suggests that clonally related
PCs disseminate to adjacent effector sites in the small intestine
following differentiating and maturation in a distal inductive
site, as was recently demonstrated in the mouse.18,19 To further
substantiate this notion, we determined the level of clonal
sharing between PCs that were isolated from different intestinal
biopsies of the same CD patients by high-throughput
sequencing analysis of their IGHV genes. Two patients were
included and single-cell suspensions from each subject were
individually processed from five intestinal biopsies and IgAPCs
were sorted into TG2-specific and non-TG2-specific cells as
previously described10 using the staining strategy shown in
Figure 2c. Next, the IGHV genes were PCR amplified and
sequenced. Unique sequences that originated within each
individual biopsy were grouped into clones. The number of
sorted cells and number of PC clones for each biopsy are given
in Supplementary Table S1 online. The degree of clonal
relatedness between different biopsies was further determined
following clonal clustering between the different biopsies.
Among non-TG2-specific PCs, the level of clonal sharing
between different biopsies ranged from 10.7 to 22.7% and from
8.2 to 13.8% in patients CD1191 and CD1192, respectively. In
comparison, the levels of clonal sharing among TG2-specific
PCs were higher and ranged from 17.9 to 73.1% and from 17.8
to 60% in the 2 patients (Figure 5a,b). Genealogy analysis
revealed that there existed PCs in all five biopsies that were
clonally related and derived from one common ancestor. A
representative clonal tree is depicted in Figure 5c.
DISCUSSION
In this work we have uncovered several novel aspects of the
anti-TG2 response in CD. The emerging picture is that the
frequency of TG2-specific PCs cells in the mucosa is
dynamically regulated and that the generation of these PCs
is taking place outside of the lamina propria with seeding of
cells, often clonally related, into distinct sites of the gut mucosa.
Recent data suggest that PCs in the small intestine are longer
lived than previously thought. Hapfelmeier et al.20 demon-
strated that inmice in a germ-free environment, and thus in the
Figure 4 Laser capture and microdissection (LCM) of plasma cell
patches rich in transglutaminase 2 (TG2)-specific ones. Sequences are
obtained fromPCRperformed on genomic DNA from dissected patches in
the lamina propria. (a) Example of a pick comprisingB20 plasma cells. (b,
c) Examples of clonal trees built from clonally related sequences derived
from the same patch ((b) clone ID 23 from Table 1) or from three different
patches ((c) clone ID 22 from Table 1) of the same patient. Data are
summarized inTable 1. The letter inside the node indicates the patch from
which the sequence comes, whereas different colors indicate sequences
derived from different, consecutive cryosections. The number next to the
line connecting the inferred sequence (gray node) and actual observed
sequences (colored nodes) represents the number of mutations by which
the two connected nodes differ.
















2 3 VH5-51 2 0.7 C, D
4 2 VH5-51 9 5.5 C
7 2 VH5-51 8 5 C
14 2 VH3-66 10 9.5 C
21 3 VH5-51 13 6.7 B, C
22 15 VH5-51 21 5.2 B, C, D
23 3 VH5-51 3 1.3 C
24 2 VH5-a 6 5.5 A, D
Clonal trees of immunoglobulin heavy chain variable (IGHV) genes of the plasma cells
(PCs) built from picks.
Clones 22 and 23 were used for the representative trees shown in Figure 4b,c.
Mutations include both silent and replacement ones.
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absence of competition, intestinal IgA-secreting cells have the
capacity to be long-lived. By colonization with given com-
mensal bacteria, specific PC antibody responses could be raised,
but without antigen persistence, the PCs disappeared within a
few months, suggesting that intestinal antibody repertoire is
characterized by constant attrition and thus represents the
dominant antigen currently present in the intestine. Mesin
et al.21 demonstrated that PCs from human small intestine
biopsies survive and secrete immunoglobulins for many weeks
in the biopsy cultures, and interleukin-6 and APRIL were
identified to be essential for plasma cell survival and antibody
secretion. TG2-specific PCs are abundant in the lesion of
patients with active CD,10 and for the maintenance of this high
abundance, lengthy survival time appears crucial. We assessed
the expression of BAFF and APRIL receptors (BCMA, TACI,
and BAFF-R) on PCs. Whereas signaling through TACI
induces class switching and antibody production, BAFF-R
and BCMA promote B-cell and plasma cell survival, respec-
tively.22–27 As shown by flow cytometry quantitation, BCMA
was expressed on the majority of PCs. In humans, both APRIL
and BAFF can bind BCMA, the latter with low avidity. BAFF-R
and TACI were expressed by a subset of cells and at variable
levels. In general, we did not observe any phenotype suggesting
differences between TG2-specific and other PCs. Although it is
likely that these receptors play a role in the development of the
PC compartment in the gut, it does not appear that the
autoimmune B-cell response in CD differs significantly from its
physiological counterpart. CD patients and healthy controls
appeared to have similar expression levels of BCMAand BAFF-
R, whereas we observed a minor (and not statistically
significant) increase in the levels of TACI in CD patients.
We found that the number of TG2-specific PCs in the small
intestinal mucosa drops dramatically within 6 months when
gluten is withdrawn from the diet. IgA and IgM PCs of the gut
express cell surface immunoglobulin.21 Thus conceivably,
recognition of antigen by surface immunoglobulin could allow
PCs to sense antigen and this could explain how PCs in the gut
aremaintained by antigen persistence and by attrition. Removal
of gluten likely does not lead to removal of TG2 antigen
available to gut PCs, and hence this is hardly the explanation for
the observed drop of TG2-specific PCs. Possibly, however, it
could relate to cessation of presentation of antigen by PCs to T
cells that would affect the survival niche for the PCs. Is has been
suggested that inCD, gluten-specific T cellsmay provide help to
TG2-specific B cells via hapten-carrier-like complexes of gluten
and TG2.28,29 If such gluten–TG2 complexes can be taken up via
surface immunoglobulinofTG2-specificPCs and thePCspresent
gluten antigen via scarcely expressed human leukocyte antigen-
DQmolecules, removal of gluten from the dietwould affect T-cell
activation and thereby survival of TG2-specific PCs.
Importantly, we observed that some TG2-specific PCs were
detectable at low frequency even at late time points. One subject
still had 4% of the PCs being TG2 specific after 6 months of
GFD. This subject was the one with the highest frequency of
TG2-specific PCs at diagnosis (18%). It would be interesting to
analyze earlier and/or closer time points and to compare them
with serum antibody titers.7 However, because of the current
guidelines for the CD diagnostic workup, such samples are
Figure 5 Clonal sharing between plasma cells (PCs) from different duodenal biopsies of patients with active celiac disease. Heat maps denoting the
level of clonal relatedness between PCs that were collected from five different small intestinal biopsies from two celiac patients: (a) CD1191 and (b)
CD1192. Single-cell suspensions were prepared from small intestinal biopsies, immunoglobulin A (IgA) PCs were further sorted for transglutaminase 2
(TG2)-specific and non-TG2-specific PCs, and their immunoglobulin heavy chain variable (IGHV) genes were sequenced. Clonal relatedness of PCs
fromdistinct biopsies was determined following clonal clustering between the different populations (seeMethods for detailed description). The left panels
depict results from non-TG2-specific plasma cells, whereas the right panels depict results from TG2-specific plasma cells. The number of PC clones in
each biopsy is shown in the diagonal across each diagram. The numbers of clones that are shared between biopsies are displayed and percentages are
calculated as a fraction from the total number of clones from the biopsy on the horizontal axis. (c) A representative lineage tree that illustrates clonal
sharing between five different biopsies of subject CD1191.
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difficult to obtain. Notwithstanding, it appears clear that many
TG2-specific PCs disappear rapidly after removal of the diet
and few remain in the mucosa. In future studies it will be
interesting to analyze in depth differences in phenotype and
transcription factors between PCs that disappear quickly and
PCs that remain when CD patients start the GFD.
It is well known that TG2-specific antibodies disappear from
the circulation within months after the commencement of the
GFD.7,30 It is thus surprising that we did not observe a clear
correlation between reduction of the serum titer and disap-
pearance of the PCs at the intestinal level in the GFD-treated
patients. TG2-specific PCs were present in 5 out of 6 samples
collected after 6 months of GFD, despite seronegativity. Several
factors are relevant to this observation. First, in situ detection of
anti-TG2 antibodies can precede appearance in serum and
hence the two are not necessarily correlated. Moreover,
compliance to a strict GFD, or even inadvertent gluten intake
(gluten being increasingly present in processed foods), may
suffice to trigger local, limited secretion that does not match
serology results. Furthermore, we did not observe any
correlation between the antibody serum titer and the frequency
of TG2-specific PCs in the lesion. It is likely that the absolute
amount, rather than the frequency, of TG2-specific PCs could
correlate with serum titer. The absolute amounts of PCs will
depend on the degree of plasmacytosis, the size of the affected
small intestine, the volume of circulating blood, and the degree
of spillover from the intestinal compartment. We did not
analyze for these factors, although preliminary data from one
patient showed comparable amounts of TG2-specific PCs in
individual biopsies sampled at the same time. Finally, it cannot
be excluded that at least some of the TG2 antibodies in the
blood are produced at sites outside of the gut, like lymph nodes,
spleen, and bonemarrow, or from circulating plasmablasts, and
although this topic is arduous to address because of the
challenges in collecting proper samples, it represents a scenario
that has implications that possibly go beyond CD.
Previously, we reported that TG2-specific PCs did not
express the proliferation marker Ki-67, suggesting that their
abundance is not a direct consequence of sustained local
expansion.10 However, the Ki-67 marker accumulates upon
sustained cell division, and it may not be expressed if cells
undergo cell proliferation at a slow, homeostatic rate. It should
also be noted that immunofluorescence may not be sensitive
enough for this type of analysis, and that flow cytometry
approaches could provide better readouts. Cell division is also
necessary for accumulation of mutations in antibody genes.
Although not commonly acknowledged, there is very clear
evidence formutations occurring outside of germinal centers, at
least in some contexts in mice.31 In addition, it has been
suggested that precursors of intestinal antibody-forming cells
may undergo somatic hypermutation and/or local expansion
directly in the lamina propria,32 although evidence remains to
be substantiated. To determine whether intestinal PCs pro-
liferate locally or at a distant sitewe performed laser capture and
microdissection of TG2-specific plasma cell patches from two
patients followed by antibody gene sequencing. We obtained
and then compared sequences obtained from several different
patches; moreover, the same patch was dissected, when
possible, from consecutive slides, thus creating a tridimensional
grid of the patch and increasing the variability of the analysis.
The rationale for the analysis of this experiment is that finding
clonal sequences that differ by one or few mutations within the
same patch, and not in patches from distant areas, would be a
good indicator that the mutations occurred locally; if this were
not the case, clonal sequenceswould not be confined exclusively
to local areas. Some of the clonal trees were generated from
sequences obtained exclusively from one patch, thus possibly
suggesting some degree of local proliferation and mutation.
However, there were larger trees with sequences from several
different patches, suggesting that these clones acquired
mutations and likely expanded at a different site before
dissemination in the mucosa. To further substantiate this
notion, we undertook analysis of the antibody repertoire among
TG2-specific and non-TG2-specific PCs from five individual
biopsies of two patients with untreated CD. We indeed
observed clonal sharing among cells of the different biopsies,
particularly among the TG2-specific PCs where the degree of
sharing ranged from 20% to 60–70%. These findings suggest
that the PCs of the duodenum clonally expand before seeding
into themucosa, although the fact that small trees could be built
exclusively from sequences found in one patch indicates that
the possibility of local expansion andmutation, at least to some
extent, cannot be completely ruled out. In general, our findings
are consistent with recent observations in mouse models.18,19
We interpret the extensive degree of clonal sharing between
TG2-specific PCs of individual biopsies likely to reflect an
expansion of dominant clones at inductive sites that is followed
by seeding of PCs into large areas of the small intestine.
Although anti-TG2 antibody deposits are usually visualized
by the classical CUB7402/IgA staining,11we found that deposits
can be observed using the antigen as bait. By staining with
biotin-TG2 in combination with an anti-IgA (Figure 1f), we
confirmed the presence of subepithelial deposits, but also
detected TG2-specific antibodies inside epithelial cells and on
the brush border. In fact, most IgA produced by intestinal PCs
are dimeric, with two molecules bound together by the J-chain
polypeptide. The J-chain interacts with the polymeric Ig
receptor at the basal side of epithelial cells, resulting in transport
across the epithelium and into the lumen. It is conceivable that
anti-TG2 antibodies bind the antigen in the subepithelial layer
and are co-transported together with it across the epithelium;
this is further suggested by the presence of TG2 itself
(colocalizing with IgA) in the epithelium and on the brush
border, as shown in Figure 1g and as suggested by figures from
a number of other publications.12,33–35 This allows us to
speculate on a model that builds upon previous observations
fromMatysiak-Budnik et al.,36 who suggested that anti-gliadin
IgA antibodies are exported in the gut lumen, where they bind
gluten and transport it across the epithelium back to the lamina
propria, via a retrotranscytosis mechanism mediated by the
transferrin receptor (CD71). In addition to anti-gliadin IgA, it
may also be that TG2 at the brush border can sample gluten
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peptides by enzymatically acting on them, and these are
retrotranscytosedwith anti-TG2 IgA (or IgM37). TG2 retains its
enzymatic activity when bound to antibodies.10 In addition, it
has been shown that the majority of peptides representing
preferred substrate for TG2 harbor known gluten T-cell
epitopes,38 and that epitopes frequently recognized by patient
T cells showed a significant higher level of deamidation
compared with those less frequently recognized.39 Other
groups have proposed mechanisms that could mediate this
or similar transport systems; Rauhavirta et al.40 also implicated
a role for celiac IgA that necessitates TG2 enzymatic activity,
and Lebreton et al.41 substantiated some of these finding,
further reintroducing CD71 in the game of play and also
suggesting a role for the enzymatic activity of TG2. These are
attractive models that require further study, including the
development of an objective quantitative measurement system
for antibody deposits in relation to its significance in CD.
In summary, the findings described here shed new light on
the characteristics of the anti-TG2 B-cell response in the
intestinal mucosa of patients affected by celiac disease.
Importantly, the general approach can be applied to similar
conditions where the role and especially the origin of
(auto)antibodies is unclear. For instance, dermatitis herpeti-
formis and gluten ataxia (the skin and central nervous system
manifestations of gluten sensitivity, respectively, occurring in
up to 10% of CD patients) are characterized by the local
presence of TG3-IgA and TG6-IgA deposits.42,43 Relevant
diseases where local presence of autoantibodies is thought to be
important but is scarcely understood include multiple sclerosis
(nervous system), rheumatoid arthritis (joints), and others. The
approaches described here may help to further our knowledge
of these daunting disorders.
METHODS
Patient material. Adult CD patients were diagnosed according to
standard criteria, including human leukocyte antigen genotyping,
anti-TG2 serum titer, and histological analysis of small intestinal
biopsy.44 The same criteria were used to exclude CD diagnosis in
controls. Ethical approval for study of Norwegian subjects was
obtained from the Regional Ethics Committee in South-Eastern
Norway (project S-97201). Each study subject gave written informed
consent. Duodenal biopsy specimens were obtained by gastro-
duodenoscopy. Tissue sections of biopsies of seven CD patients with
active disease, from three CD patients treated with a GFD and two
healthy control subjects were studied. In addition, biopsies from five
untreated CD patients and five healthy controls were processed and
used for flow cytometry analysis and PCs of biopsies from two
untreated CD patients were processed for high-throughput
sequencing. Ethical approval for study of the Finnish subjects was
obtained from the Ethics Committee of Tampere University Hospital,
and each subject provided written informed consent. Samples from 15
CD patients and 4 nonceliac controls suffering from dyspepsia were
studied. From these subjects small-bowel mucosal biopsies were taken
eitherwith an adult-sizeWatson capsule from the proximal jejunumor
upon endoscopy with forceps from the distal duodenum. For each
subject, part of the sampleswere snap-frozen and embedded in optimal
cutting temperature compound (OCT, Tissue-Tec, Miles, Elkhart, IN)
for storing at  70 1C, whereas the rest of the biopsy specimens were
paraffin embedded. Serum IgA class antibodies against TG2 were
detected by enzyme-linked immunosorbent assay using human
recombinant TG2 as antigen, with a cutoff line of 5.0Uml 1 (Celikey,
Phadia, Freiburg, Germany).
Immunofluorescence on intestinal biopsy cryosections. Immu-
nofluorescence experiments were done as reported before.10 The
technique is based on the ability of biotinylated TG2, followed by
labeled streptavidin, to selectively bind TG2-specific antibody deposits
inside plasma cells. Briefly, biopsy specimens stored at  70 1C were
thawed and rinsed with phosphate-buffered saline (PBS). Primary
reagents were incubated in 1.2% bovine serum albumin in PBS for
45min at room temperature (RT). Sections were extensively rinsed
with PBS, and secondary reagents were incubated in 12%bovine serum
albumin in PBS for 30min at RT. Sections were rinsed with PBS and
mounted. The following antibodies and reagents were used: mouse
anti-CD138 (1:25, AbDSerotec, Kidlington, UK), recombinant human
TG2 produced in Escherichia coli and biotinylated as reported before10
(5 mgml 1), mouse anti-TG2 monoclonal antibody CUB7402
(1:1,000, Neomarkers, Fremont, CA), anti-TACI (1:200, sc-7332
N-19), anti-BCMA (1:200, sc-11743N-16), and anti-BAFF-R (1:150,
eBioscience 8A7, San Diego, CA) primary antibodies. Secondary
antibodies were used as follows: Alexa Fluor 546/488/649-conjugated
anti-goat, anti-mouse, and anti-rabbit polyclonal antibodies (1:1,000,
Life Technologies, Carlsbad, CA), streptavidin-cy2 (1:1,000, GE
Healthcare Biosciences, Pittsburgh, PA), streptavidin-cy3 (1:2,000, GE
Healthcare Biosciences), anti-mouse-cy3 (1:1,500, Southern Biotech,
Birmingham, AL), and anti-IgA fluorescein isothiocyanate (1:40,
Dako). DAPI (4’,6-diamidino-2-phenylindole) was used to coun-
terstain nuclei.
Flowcytometry. The frequency of TG2-specific PCs in small intestinal
biopsies was determined using flow cytometry as previously repor-
ted.10 The expression levels of BCMA, BAFF-R, andTACI on intestinal
PCs that either stained positive or negative for TG2were also examined
using flow cytometry of single-cell suspensions of biopsies with Bir-A
biotinylated TG2 multimerized on fluorescently labeled streptamers.
In short, recombinant human TG2 was expressed in Sf9 insect cells by
baculovirus with a Bir-A recognition site at its N-terminus. TG2 was
biotinylated with Bir-A enzyme (Avidity, Aurora, CO), and incubated
with allophycocyanin-labeled streptamers (IBA, Gottingen, Germany)
in a 4:1 molar ratio for 1 h to generate TG2-multimers. Cryopreserved
single-cell suspensions that were prepared from gut biopsies were
thawed and stained with allophycocyanin-labeled TG2-multimer for
45min on ice. IgA fluorescein isothiocyanate (Southern Biotech),
Brilliant Violet 570 CD3, CD14, and CD38 PerCp-Cy5.5 (BioLegend,
San Diego, CA), CD19 Pacific Blue (BD Biosciences), CD27 PE-Cy7
(eBioscience), and either BCMA, BAFF-R, or TACI (all phycoerythrin
(PE) conjugated, BioLegend) were added for the last 20min for
staining of specific cellular lineage markers. FMO control (i.e.,
Fluorescence Minus One) was used to properly interpret the
expression of BCMA, BAFF-R, and TACI by staining single-cell
suspensions of each subject with a combination of all antibodies and
TG2-multimers except the PE-conjugated antigens. Samples were
acquired on LSRFortessa (BD Biosciences, San Jose, CA) and the data
were analyzed by FlowJo, version 10.0.7 (Ashland, OR).
Immunohistochemistry and laser capture andmicrodissection. For
laser capture and microdissection, 7 mm thick cryosections from
specimens of patients were cut on 2 mm PEN-membrane slides (Leica,
BuffaloGrove, IL). Sectionswere fixed in acetone for 10min and stored
at  80 1C. For laser capture and microdissection, a Leica LMD6500
instrument equipped with an optical microscope was used, and
sections were therefore stained by immunohistochemistry. Briefly,
slides were thawed and rinsed in PBS. Primary reagents (mouse anti-
CD138 or recombinant humanbiotinylated TG2produced inE. coli, as
reported above) were diluted in 1% bovine serum albumin in PBS and
added to the slide for 45min at RT in a moist chamber. Slides were
extensively rinsed and secondary reagents (goat anti-mouse IgG-HRP,
1:500, Santa Cruz (Dallas, TX), or SA-HRP, 1:500, Southern Biotech)
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in 1%bovine serum albumin in PBSwere added for 30min at RT. After
extensive washing with PBS, development was performed by adding
3-amino-9-ethylcarbazole substrate (Sigma, St Louis, MO) and
incubating for 2 to 20min until proper development occurred. Slides
were carefully washed with water to remove all salts, dried at RT, and
then stored at 4 1C until necessary. Dissections were performed in the
caps of 0.5ml tubes, to which 10 ml of digestion buffer (50mM Tris-
HCl, 50mM KCl, 0.63mM EDTA, 0.22% Igepal, 0.22% Tween-20, and
0.8mgml 1 proteinase K) were added. After dissection of plasma cell
patches in the caps, these were closed and the tubes spinned. The
samples were addedwith a drop ofmineral oil, digested at 55 1C for 2 h,
followedby inactivation of proteinaseK at 90 1C for 5min, and used for
PCR amplification of antibody genes directly from genomic DNA.
PCR and analysis of IGHV genes from plasma cell picks. A
seminested PCR was performed in 50ml using the high-fidelity Pfu-
Turbo DNA polymerase enzyme (Agilent, Santa Clara, CA) as per the
manufacturer’s instructions. Primers used in the primary and secondary
PCRswere asdescribedbyKuppers.45TheVH1,VH3, andVH5primers
wereusedas amix in theprimaryPCR, and individually in the secondary
PCR.Antisense primers in the J regionswereusedasoriginallydescribed
in the protocol.45 PCR products were purified and cloned in the Zero
Blunt TOPO PCR cloning kit for sequencing (Life Technologies) as per
themanufacturer’s instructions, and individual colonieswere sequenced
at the Keck DNA sequencing facility at Yale. Analysis of the sequences
was performed as follows: preprocessing was carried out using pRESTO
(http://clip.med.yale.edu/pRESTO) as previously described.46,47 V(D)J
germline segmentswere determined using IMGT/HighV-QUEST48 and
divided into clonally related groups based on common V gene, J gene,
and junction region length. Lineage trees were constructed for each
clonal group with the dnapars application of PHYLIP.46
High-throughput sequencing of IGHV genes of isolated plasma
cells. Single-cell suspensions were prepared from individual biopsies
taken from twoCDpatientswith active disease and cryopreserved until
used. TG2 multimerized on PE-labeled streptavidin was used for
identifying TG2-specific or non-TG2-specific PCs from single-cell
suspensions as previously described,10 and cells were sorted directly
into 25ml catch buffer (10mM dithiothreitol and 2Uml 1 RNAsin
(Promega, Madison, WI) in PBS). For complementary DNA (cDNA)
synthesis, 1 mg of randomhexamers (Roche, Basel, Switzerland), 0.45%
v/v NP-40, 1 ml RNAsin 40Uml 1 (Promega), and diethylpyr-
ocarbonate-treated water (to a final volume of 50 ml) were added; the
mixwas incubated at 65 1C for 5min andput on ice.Next, 20 ml 5 RT
buffer, 7 ml dithiothreitol 100mM, 9 ml of 10mMdNTP-Mix (Promega),
1.5ml RNAsin 40U ml 1 (Promega), 1.8 ml superscript III (Life
Technologies), and 14ml diethylpyrocarbonate-treated water were
added. The cDNA was synthesized at 42 1C for 10min, 25 1C for
10min, 50 1C for 60min, and 94 1C for 5min. The Ig heavy chain VH
region was amplified between framework (FR) 2 and J from cDNA
using two consecutive PCRs. For the first PCR, six forward primers, i.e.,
FR2 VH1–6, and a single IGHJ reverse primer were used.49,50 Both
forward and reverse primers included six nucleotides that were used as
indexes for the different subsets and that were further followed by six
random nucleotides and partial Illumina adapters (San Diego, CA).
The first PCR was performed using AmpliTaq Gold polymerase (Life
Technologies) as follows: 95 1C for 7min, 25 PCR cycles (95 1C for 30 s,
60 1C for 45 s, 72 1C for 90 s), and 72 1C for 10min. A second PCRwas
designed so that it included Illumina adapter sequences using Qiagen
Multiplex PCR as follows: 95 1C for 15min, 10 PCR cycles (95 1C for
30 s, 60 1C for 45 s, 72 1C for 90 s), and 72 1C for 10min. Final
amplicons libraries were extracted from agarose gel (Qiagen, Venlo,
The Netherlands) and paired-end sequencing of 250 base pairs was
performed using Illumina MiSeq. Primers sequences are given in
Supplementary Table S2. Raw sequencing data were processed by
pRESTO, and unique sequences that originated within each individual
biopsy were grouped into clones as previously described.51
SUPPLEMENTARYMATERIAL is linked to the online version of the paper
at http://www.nature.com/mi
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